Ventures, Llcvv Manager Llc... Net Worth

The estimated Net Worth of Ventures, Llcvv Manager Llc... is at least $717 Tausend dollars as of 2 April 2018. Ventures Llc owns over 375,000 units of Homology Medicines Inc stock worth over $716,886 and over the last 7 years Ventures sold FIXX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Llc FIXX stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the Homology Medicines Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Ventures bought 375,000 units of FIXX stock worth $6,000,000 on 2 April 2018.

The largest trade Ventures's ever made was buying 375,000 units of Homology Medicines Inc stock on 2 April 2018 worth over $6,000,000. On average, Ventures trades about 375,000 units every 0 days since 2018. As of 2 April 2018 Ventures still owns at least 770,845 units of Homology Medicines Inc stock.

You can see the complete history of Ventures Llc stock trades at the bottom of the page.

What's Ventures Llc's mailing address?

Ventures's mailing address filed with the SEC is 40 BROAD STREET, SUITE 20140 BROAD STREET, SUITE 201, , BOSTONBOSTON, MAMA, 0210902109.

Insiders trading at Homology Medicines Inc

Over the last 7 years, insiders at Homology Medicines Inc have traded over $108,214,465 worth of Homology Medicines Inc stock and bought 3,033,333 units worth $51,999,993 . The most active insiders traders include Steven Gillis, James Edeerfield Management... und Kush Parmar. On average, Homology Medicines Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,785. The most recent stock trade was executed by Paul Alloway on 25 March 2024, trading 23,530 units of FIXX stock currently worth $21,883.

What does Homology Medicines Inc do?

homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Complete history of Ventures Llc stock trades at Homology Medicines Inc

Homology Medicines Inc executives and stock owners

Homology Medicines Inc executives and other stock owners filed with the SEC include:

• Arthur Tzianabos,
  President, Chief Executive Officer, Director
• Tim Kelly,
  Chief Technical Operations Officer
• Albert Seymour,
  Chief Scientific Officer
• W. Bradford Smith,
  Chief Financial Officer, Treasurer and Secretary
• Dr. Arthur O. Tzianabos Ph.D.,
  Pres, CEO & Director
• Dr. Albert Seymour Ph.D.,
  Chief Scientific Officer
• W. Bradford Smith CPA, M.B.A.,
  CFO & Treasurer
• Alise Reicin,
  Independent Director
• Kush Parmar,
  Independent Director
• Mary Thistle,
  Independent Director
• Richard Gregory,
  Independent Director
• Matthew Patterson,
  Independent Director
• Steven Gillis,
  Independent Director
• Jeffrey Poulton,
  Director
• Gabriel Cohn,
  Chief Medical Officer
• Cara Mayfield,
  Director of Corp. Communications
• Dr. Deborah Kinch Ph.D.,
  Chief Devel. Officer
• Dr. Julie Jordan M.D.,
  Sr. VP and Head of Clinical Devel. & Operations
• Michael Blum M.B.A.,
  Chief Commercial Officer
• Dr. Gabriel M. Cohn M.B.A., M.D.,
  Chief Medical Officer
• Melissa Gelormini,
  VP of HR
• Theresa McNeely,
  Chief Communications Officer & Patient Advocate
• Dr. Paul Alloway J.D., Ph.D.,
  Chief Legal Officer & Sec.
• Timothy P. Kelly M.B.A.,
  Chief Operating Officer
• Dr. Saswati Chatterjee Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Ventures Iv, L.P.5 Am Co In...,
  
• Ventures Iv, L.P.5 Am Partn...,
  
• Institutes For Bio Medical ...,
  
• Ventures, Llcvv Manager Llc...,
  
• Holdings (Private) Ltd Full...,
  
• Cameron Wheeler,
  Director
• Siyamak Rasty,
  Chief Operating Officer
• James Edeerfield Management...,
  
• James Edeerfield Management...,
  
• Venture Fund Viii, L.P.Arch...,
  
• Springs Capital Management ...,
  
• Venture Fund Viii, L.P.Arch...,
  
• Charles Jr Michaud,
  See Remarks
• Paul Alloway,
  See Remarks
• Michael Lee Blum,
  Chief Commercial Officer
• Julie Jordan,
  Chief Medical Officer